PHARMACOKINETICS OF AZATHIOPRINE AFTER REPEATED ORAL AND SINGLE INTRAVENOUS ADMINISTRATION

被引:15
作者
ELYAZIGI, A
WAHAB, FA
机构
[1] Pharmacokinetics Laboratory, Pharmacology and Toxicology Section, Biological and Medical Research Department, King Faisal Specialist Hospital and Research Centre, Riyadh
关键词
D O I
10.1002/j.1552-4604.1993.tb04698.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of azathioprine (AZN) were examined in 28 renal transplant patients treated orally with 25 to 150 mg AZN once daily in combination with cyclosporin A and prednisone, and after single intravenous (IV) injection of 5 mg/kg AZN using the rabbit as an in vivo model. The steady-state concentrations of AZN observed in these patients ranged from 6 to 583 mug/L, and the interday coefficients of variation of the concentration in three randomly selected patients were 38%, 12%, and 4.6%. The frequency distribution pattern of the apparent oral clearance (TCL(or)) of AZN separates the patients almost equally into poor (TCL(or) = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCL(or) = 5 to 12 L/hour.kg). The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, V(c), and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively. The large variability in the pharmacokinetic parameters of AZN in patients and even in rabbits under carefully controlled conditions that may be ascribed to the complexity of its metabolism necessitates a careful approach to its dose selection.
引用
收藏
页码:522 / 526
页数:5
相关论文
共 16 条
[1]   6-THIOPURINES AS SUBSTRATES AND INHIBITORS OF PURINE OXIDASES - A PATHWAY FOR CONVERSION OF AZATHIOPRINE INTO 6-THIOURIC ACID WITHOUT RELEASE OF 6-MERCAPTOPURINE [J].
CHALMERS, AH ;
KNIGHT, PR ;
ATKINSON, MR .
AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1969, 47 :263-+
[2]   AZATHIOPRINE METABOLISM - PHARMACOKINETICS OF 6-MERCAPTOPURINE, 6-THIOURIC ACID AND 6-THIOGUANINE NUCLEOTIDES IN RENAL-TRANSPLANT PATIENTS [J].
CHAN, GLC ;
ERDMANN, GR ;
GRUBER, SA ;
MATAS, AJ ;
CANAFAX, DM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) :358-363
[3]   HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE-INDEPENDENT TOXICITY OF AZATHIOPRINE IN HUMAN-LYMPHOBLASTS [J].
DALKE, AP ;
KAZMERS, IS ;
KELLEY, WN .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (16) :2692-2695
[4]  
De MIRANDA P, 1973, J Pharmacol Exp Ther, V187, P588
[5]  
DING TL, 1980, CLIN PHARMACOL THER, V27, P250
[6]  
ELION GB, 1970, FED PROC, V29, pA607
[7]   THEOPHYLLINE ABSORPTION AND DISPOSITIONS IN RABBITS - ORAL, INTRAVENOUS, AND CONCENTRATION-DEPENDENT KINETIC-STUDIES [J].
ELYAZIGI, A ;
SAWCHUK, RJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1981, 70 (04) :452-456
[8]   EXPEDIENT LIQUID-CHROMATOGRAPHIC ANALYSIS OF AZATHIOPRINE IN PLASMA BY USE OF SILICA SOLID-PHASE EXTRACTION [J].
ELYAZIGI, A ;
ABDELWAHAB, F .
THERAPEUTIC DRUG MONITORING, 1992, 14 (04) :312-316
[9]  
GIBALDI M, 1975, PHARMACOKINETICS, P45
[10]  
MADDOCKS JL, 1978, CLIN SCI MOL MED, V55, pP20